Last update Sept. 2, 2022

N-{p-[2-(Dimethylamino)ethoxy]benzyl}veratramide hydrochloride

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a prokinetic from the benzamide group, a dopamine antagonist and similar to Metoclopramide. Indicated in chronic gastritis and dyspepsia. Oral administration in 3 daily doses.

Since the last update we have not found published data on its excretion in breastmilk.

Its high plasma protein binding (Domínguez 2012) makes it unlikely to transfer into breastmilk in significant amounts.

It has very few bibliographical references, and is sold in few countries.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.


  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

N-{p-[2-(Dimethylamino)ethoxy]benzyl}veratramide hydrochloride is Itopride Hydrochloride in Chemical name.

Is written in other languages:


N-{p-[2-(Dimethylamino)ethoxy]benzyl}veratramide hydrochloride belongs to this group or family:


Main tradenames from several countries containing N-{p-[2-(Dimethylamino)ethoxy]benzyl}veratramide hydrochloride in its composition:


Variable Value Unit
Molecular weight 395 daltons
Protein Binding 96 %
pKa 14.71 -
Tmax 0.5 - 0.75 hours
2.95 - 5.7 hours


  1. Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ. Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers. Drug Des Devel Ther. 2014 Jan 15;8:123-8. Abstract
  2. Dominguez. Itoprida (Aflusan). Ficha técnica. 2012 Full text (in our servers)
  3. Cho KJ, Cho W, Cha KH, Park J, Kim MS, Kim JS, Hwang SJ. Pharmacokinetic and bioequivalence study of itopride HCl in healthy volunteers. Arzneimittelforschung. 2010;60(3):137-40. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM